Cody A Ramirez, Michelle Becker-Hapak, Kartik Singhal, David A Russler-Germain, Felix Frenkel, Erica K Barnell, Ethan McClain, Sweta Desai, Timothy Schappe, Onyinyechi C Onyeador, Olga Kudryashova, Vladislav Belousov, Alexander Bagaev, Elena Ocheredko, Susanna Kiwala, Jasreet Hundal, Zachary L Skidmore, Marcus P Watkins, Thomas B Mooney, Jason Walker, Kilannin Krysiak, Felicia Gomez, Catrina C Fronick, Robert S Fulton, Robert D Schreiber, Neha Mehta-Shah, Amanda F Cashen, Brad S Kahl, Ravshan Ataullakhanov, Nancy L Bartlett, Malachi Griffith, Obi L Griffith, Todd A Fehniger
Personalized cancer vaccines designed to target neoantigens represent a promising new treatment paradigm in oncology. In contrast to classical idiotype vaccines, we hypothesized that 'polyvalent' vaccines could be engineered for the personalized treatment of follicular lymphoma (FL) using neoantigen discovery by combined whole exome sequencing (WES) and RNA sequencing (RNA-Seq). Fifty-eight tumor samples from 57 patients with FL underwent WES and RNA-Seq. Somatic and B-cell clonotype neoantigens were predicted and filtered to identify high-quality neoantigens...
May 7, 2024: Blood Advances